Funded with Support from

The etiology and genetics, pathophysiology, diagnosis, and management of Stargardt disease, Best disease, oculocutaneous albinism, and X-linked retinoschisis are discussed in this chapter.

In this paper, researchers compared retinoblastoma treatment outcomes in patients worldwide.

Phase 2 results show that selective ophthalmic artery chemotherapy with melphalan can be used as a first-line therapy for retinoblastoma.

In this video, Dr. Emily McCourt presents a discussion of journal articles concerning long-term visual outcomes following head trauma with retinal hemorrhage, predictive factors of rhegmatogenous retinal detachment in children, and pearls for managing pediatric retinal detachments.

Dr. Gil Binenbaum leads a series of talks on retinopathy of prematurity (ROP), followed by a panel discussion, to provide an overview of updates on ROP for the year 2020.

Dr. Nathan Radcliffe discusses use of selective laser trabeculoplasty (SLT) on the patient using a single glaucoma medication with intraocular pressure (IOP) above the target level. He refers to the LIGHT trial, which compares SLT and eye drops for first-line treatment of ocular hypertension and glaucoma.

In this population-based analysis, investigators evaluated ophthalmologic disorders associated with autism spectrum disorder.

The ROP 2020 Update, jointly sponsored by the Academy and the International Pediatric Ophthalmology and Strabismus Council (IPOSC), provides a 2-hour review with more than 30 panelists discussing a series of prerecorded lectures from worldwide ROP experts.

Dr. Friedman moderates this virtual journal club with Drs. Reem, Daikonis, and Jung. Articles included: Diagnostic criteria in pediatric intracranial hypertension (Rachel Reem, MD); Long-term outcomes of corneal cross-linking for keratoconus in pediatric patients (Vasilios F. Diakonis, MD, PhD); and Validation of WINROP for detecting retinopathy of prematurity in a North American cohort of preterm infants (Jennifer L. Jung, MD).